BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Monday, June 16, 2025
Home
»
Newsletters
» BioWorld
BioWorld
Feb. 9, 2006
View Archived Issues
Entereg’s Positive Phase III Data Drive Up Adolor’s Stock
Adolor Corp. unveiled positive Phase III data on Entereg (alvimopan), its partnered product for postoperative ileus, boosting shares in the company. (BioWorld Today)
Read More
Immtech Prices $16M Public Offering; EpiCept Adds $11M
Read More
PDZ Binding Domain Origins Determinant Of Flu Severity
Read More
Optimized Proteases Garner $30M In Catalyst’s Series B
Read More
Oscient Gets Ramoplanin Rights Back From Pfizer
Read More
Clinic Roundup
Read More
Other News To Note
Read More
